Since then, a series of differentiation regulators, including retinoic acids, granulocyte-macrophage colony-stimulating factor, and interleukin-3, have been used in several tumor types such as osteosarcoma, acute myeloid leukemia (AML), pancreatic cancer, liver cancer, and NB (de Thé, 2018). This evidence concerns the gene CSF2 and acute myeloid leukemia.